论文部分内容阅读
目的:用动态血糖监测系统评价加用沙格列汀前后二甲双胍治疗2型糖尿病患者血糖变异性和低血糖发生率及体重的差异。方法:选取已经接受至少3个月二甲双胍治疗的2型糖尿病患者73例,联合口服沙格列汀治疗12周,联合前后采用动态血糖检测的方法,计算血糖变异指标、平均血糖、低血糖人次、空腹及餐后平均血糖情况,评价联合治疗前后患者血糖波动情况、低血糖发生率及体重变化的差异。结果联合沙格列汀治疗后,平均血糖波动幅度、平均血糖水平、血糖最高值、平均餐后血糖均低于联合治疗前,血糖最低值高于治疗前,差异具有统计学意义(P<0.05),低血糖事件少在联合治疗组与二甲双胍单药组相似,差异无统计学意义(P>0.05),两组体重无显著变化。结论:起始二甲双胍和沙格列汀联合治疗,较二甲双胍单药治疗对血糖控制更好,且不增加低血糖发生率和体重。
OBJECTIVE: To evaluate the difference of blood glucose and the incidence of hypoglycaemia and body weight in patients with type 2 diabetes mellitus plus metformin before and after the addition of saxagliptin with an active glucose monitoring system. Methods: Totally 73 patients with type 2 diabetes mellitus who had been treated with metformin at least 3 months were enrolled in the study. After oral administration of saxagliptin for 12 weeks, the indexes of blood glucose, blood glucose, blood glucose, Fasting and average postprandial blood glucose, evaluate the patients before and after treatment of blood glucose fluctuations, the incidence of hypoglycemia and body weight differences. Results After combined with saxagliptin, the mean blood glucose level, mean blood glucose level, the highest blood glucose level and the mean postprandial blood glucose level were all lower than those before the combination therapy, with the lowest blood glucose level being higher than before treatment (P <0.05 ), Low incidence of hypoglycemia in combination therapy group and metformin single drug group similar, the difference was not statistically significant (P> 0.05), no significant changes in body weight. CONCLUSION: The combination of metformin and saxagliptin is superior to metformin alone in controlling glycemic control without increasing the incidence of hypoglycaemia and body weight.